KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Inventory (2016 - 2025)

Pfizer (PFE) has disclosed Inventory for 17 consecutive years, with $10.7 billion as the latest value for Q4 2025.

  • Quarterly Inventory fell 1.82% to $10.7 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.7 billion through Dec 2025, down 1.82% year-over-year, with the annual reading at $10.7 billion for FY2025, 1.82% down from the prior year.
  • Inventory for Q4 2025 was $10.7 billion at Pfizer, down from $11.5 billion in the prior quarter.
  • The five-year high for Inventory was $11.7 billion in Q3 2024, with the low at $8.5 billion in Q2 2021.
  • Average Inventory over 5 years is $10.2 billion, with a median of $10.3 billion recorded in 2023.
  • The sharpest move saw Inventory dropped 7.05% in 2021, then grew 17.5% in 2022.
  • Over 5 years, Inventory stood at $9.1 billion in 2021, then fell by 0.86% to $9.0 billion in 2022, then rose by 13.45% to $10.2 billion in 2023, then increased by 6.5% to $10.9 billion in 2024, then fell by 1.82% to $10.7 billion in 2025.
  • According to Business Quant data, Inventory over the past three periods came in at $10.7 billion, $11.5 billion, and $11.7 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.